Publicly listed US equity REITs ended June at a median 19.1% discount to their consensus NAV per share estimates, according ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Exxon Mobil's advantaged assets and growth prospects support its stock's resilience and appeal. Click here to read an ...

B2Gold offers strong upside from undervalued assets, future cash flow growth, and reduced political risk despite pressures.

European banks' stock performance eclipsed that of their US and Asian counterparts by a wide margin in the first half, ...

Perma-Fix stands poised for growth with catalysts like Hanford DFLAW & PFAS Gen 2.0. See more on PESI stock's upside ...

UnitedHealth continued to be the largest US insurer by market capitalization during the second quarter, even as it ...

Ralph Lauren's FY 2025 revenue rose 6.75%, boosted by strong margins and U.S.-Vietnam trade benefits. Read more on RL stock ...

Recent insider purchases of Strategy stand out amidst dominant selling trends. Learn what this signals about insiders' ...

Mitsubishi UFJ stock is deserving of a lower discount rate and higher ROE expectations with its latest actions. See more on ...

Alphabet is dominating AI with innovations like Gemini and AI Mode on Google Search. Read here for more on GOOG stock here.

Centrus Energy faces steep valuation risks with unsustainable premiums, overstated backlog, and cash flow uncertainties. Read ...